Substance / Medication

Lisocabtagene maraleucel

Overview

Active Ingredient
lisocabtagene maraleucel
RxNorm CUI
2479136

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.
Elmacken Mona, Peredo-Pinto Helkha, Wang Cong et al. · Clin Cancer Res · 2024
PMID: 38324398RCT
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Abramson Jeremy S, Johnston Patrick B, Kamdar Manali et al. · Blood Adv · 2022
PMID: 36149968RCTFull text (PMC)
Comparative efficacy of lisocabtagene maraleucel in the PILOT studysecond-line chemotherapy regimens in the real world.
Ghosh Nilanjan, Sehgal Alison, Liu Fei Fei et al. · Haematologica · 2025
PMID: 39479862TrialFull text (PMC)
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.
Sehgal Alison, Hoda Daanish, Riedell Peter A et al. · Blood Adv · 2025
PMID: 40305658TrialFull text (PMC)
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser Franck, Dahiya Saurabh, Palomba M Lia et al. · Nat Med · 2024
PMID: 38830991TrialFull text (PMC)
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
Linhares Yuliya, Freytes Cesar O, Cherry Mohamad et al. · Blood Adv · 2024
PMID: 39347584TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Lisocabtagene maraleucel (substance)
SNOMED CT
1148744000
UMLS CUI
C4086001
RxNorm CUI
2479136

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.